Evidence map›Paper›PMID 31000628›Full record

ArticleThe Journal of biological chemistry2019

The redox regulator sulfiredoxin forms a complex with thioredoxin domain-containing 5 protein in response to ER stress in lung cancer cells.

Hedy A Chawsheen, Hong Jiang, Qi Ying, Na Ding, Pratik Thapa, Qiou Wei

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Thioredoxin Domain Containing 5 (TXNDC5): Friend or Foe?Current issues in molecular biology · 2024
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. The role and mechanism of TXNDC5 in diseases.European journal of medical research · 2022
    Review
  8. Article
  9. Hyperoxidation of Peroxiredoxins and Effects on Physiology ofAntioxidants (Basel, Switzerland) · 2021
    Article
  10. Identification ofFrontiers in oncology · 2021
    Article
  11. mFrontiers in oncology · 2021
    Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hedy A ChawsheenFrom the Department of Toxicology and Cancer Biology and.ORCID 0000-0002-4075-1189
Hong JiangFrom the Department of Toxicology and Cancer Biology and.
Qi YingFrom the Department of Toxicology and Cancer Biology and.
Na DingFrom the Department of Toxicology and Cancer Biology and.
Pratik ThapaFrom the Department of Toxicology and Cancer Biology and.
Qiou WeiFrom the Department of Toxicology and Cancer Biology and qiou.wei@uky.edu.ORCID 0000-0001-6752-8692

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI KATHLEEN L. O'CONNOR · 2013 to 2026
$38.3M
Role of Sulfiredoxin in Colorectal Cancer DevelopmentR01CA222596 · NCI · UNIVERSITY OF KENTUCKY · PI WEI, QIOU · 2018 to 2022
$1.7M
NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA222596
6 · The paper itself

Abstract

Sulfiredoxin (Srx) reduces hyperoxidized 2-cysteine-containing peroxiredoxins (Prxs) and protects cells against oxidative stress. Previous studies have shown that Srx is highly expressed in primary specimens of lung cancer patients and plays a pivotal role in lung tumorigenesis and cancer progression. However, the oncogenic mechanisms of Srx in cancer are incompletely understood. In this study, we found that Srx knockdown sensitizes lung cancer cells to endoplasmic reticulum (ER) stress-induced cell death. Through MS analysis, we determined that Srx forms a complex with the ER-resident protein thioredoxin domain-containing protein 5 (TXNDC5). Using reciprocal co-immunoprecipitation, immunofluorescence imaging, subcellular fractionation, and domain-mapping assays with site-specific mutagenesis and purified recombinant proteins, we further characterized the Srx-TXNDC5 interaction. In response to ER stress but not to oxidative stress, Srx exhibits an increased association with TXNDC5, facilitating the retention of Srx in the ER. Of note, TXNDC5 knockdown in lung cancer cells inhibited cell proliferation and repressed anchorage-independent colony formation and migration, but increased cell invasion and activation of mitogen-activated protein kinases. Using immunohistochemical staining, we demonstrate that TXNDC5 is highly expressed in patient-derived lung cancer specimens. Bioinformatics analysis of publicly available data sets revealed that those with high Srx levels have significantly shorter survival and that those with high TXNDC5 levels have longer survival. We conclude that the cellular levels of Srx and TXNDC5 may be useful as biomarkers to predict the survival of individuals with lung cancer.

Indexed as

Endoplasmic Reticulum StressA549 CellsApoptosisBinding SitesCell ProliferationComputational BiologyHumansLung NeoplasmsMass SpectrometryMitogen-Activated Protein KinasesMolecular Docking SimulationMutagenesis, Site-DirectedOxidoreductases Acting on Sulfur Group DonorsPeptidesProtein BindingProtein Disulfide-IsomerasesMitogen-Activated Protein KinasesOxidoreductases Acting on Sulfur Group DonorsPeptidesProtein Disulfide-IsomerasesRecombinant ProteinsRNA, Small InterferingSRXN1 protein, humanTunicamycinTXNDC5 protein, humanantioxidantenzyme mechanismoxidative stressprotein-disulfide isomeraseprotein-protein interactionproteomicspulmonary carcinomasulfiredoxinthioredoxin-domain containing 5 (TXNDC5)tumorigenesis

Identifiers

PMID31000628
PMCPMC6552416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.